Italia markets closed

Organovo Holdings, Inc. (ONVO)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
3,3500+0,1700 (+5,35%)
Alla chiusura: 04:00PM EDT
3,3900 +0,04 (+1,19%)
Dopo ore: 04:33PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente3,1800
Aperto3,2100
Denaro3,2100 x 800
Lettera3,5500 x 900
Min-Max giorno3,2100 - 3,4100
Intervallo di 52 settimane1,7100 - 8,3000
Volume87.479
Media Volume99.911
Capitalizzazione32,581M
Beta (5 anni mensile)1,10
Rapporto PE (ttm)N/D
EPS (ttm)-1,3150
Prossima data utili08 feb 2020
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Organovo Achieves 3D Tissue Model for Crohn’s Disease

    SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional (3D) biology company focused on delivering scientific and medical breakthroughs using novel technologies including 3D bioprinting, today announces that it has successfully advanced its first inflammatory bowel disease (IBD) model to the next step of target discovery and validation for Crohn’s disease. Based on its internal data and scientific results, the company believes that its first IBD mo

  • GlobeNewswire

    UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents

    SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), and BICO (OTCPK: CLLKF, Nasdaq Stockholm: BICO.ST) announced they have reached agreement on a broad license for BICO and its affiliate companies to Organovo’s foundational patent portfolio in 3D bioprinting. Founded in 2016, BICO (formerly Cellink) is the leading bio convergence company in the world. Cellink continues to operate as a wholly owned division of BICO. Organovo exclusively licensed early bioprinting

  • GlobeNewswire

    Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents

    SAN DIEGO, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), and BICO today announced they have reached agreement on a broad license for BICO and its affiliate companies to Organovo’s foundational patent portfolio in 3D bioprinting. Founded in 2016, BICO (formerly Cellink) is the leading bio convergence company in the world. Cellink continues to operate as a wholly owned division of BICO. Organovo exclusively licensed early bioprinting work by Gabor Forgacs, its scientifi